CoChat

Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies

Open access

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index; none of the 65 sources its claims cite is checked for support yet.

Abstract

Most targeted cancer therapies fail to achieve complete tumor regressions or attain durable remissions. To understand why these treatments fail to induce robust cytotoxic responses despite appropriately targeting oncogenic drivers, here we systematically interrogated the dependence of cancer cells on the BCL-2 family of apoptotic proteins after drug treatment. We observe that multiple targeted therapies, including BRAF or EGFR inhibitors, rapidly deplete the pro-apoptotic factor NOXA, thus creating a dependence on the anti-apoptotic protein MCL-1. This adaptation requires a pathway leading to destabilization of the NOXA mRNA transcript. We find that interruption of this mechanism of anti-apoptotic adaptive resistance dramatically increases cytotoxic responses in cell lines and a murine melanoma model. These results identify NOXA mRNA destabilization/MCL-1 adaptation as a non-genomic mechanism that limits apoptotic responses, suggesting that sequencing of MCL-1 inhibitors with targeted therapies could overcome such widespread and clinically important resistance.

Overview

CoChat Summary

TL;DR

Multiple targeted therapies rapidly deplete pro-apoptotic NOXA by destabilizing its mRNA via ZFP36/TTP, shifting MCL-1 binding toward BIM and creating adaptive MCL-1 dependence. Sequential MAPK-pathway inhibition followed by MCL-1 inhibition enhanced apoptosis and tumor regression in cell lines and murine melanoma models.

Key findings

  • In an siRNA sensitization screen across 21 cancer cell lines with distinct driver oncoproteins, suppression of MCL1 strongly sensitized most cell lines to targeted therapies independent of lineage, driver, or drug; other anti-apoptotic BCL-2 family members did not consistently affect responses.
  • Dynamic BH3 profiling showed increased MCL-1 dependence after BRAF/MEK inhibition in A375M melanoma cells, after imatinib in KIT-mutant GIST, after gefitinib in EGFR-mutant lung cancer, and in freshly obtained primary melanoma cells after BRAF, MEK, or ERK inhibitors; MCL-1 dependence was minimally changed in a BRAF/MEK-resistant patient sample and a BRAF/NRAS wild-type melanoma.
  • NOXA mRNA loss was rapid (half-life ~2 h); actinomycin D plus PLX4720 enhanced NOXA mRNA loss, ZFP36 knockdown blocked NOXA mRNA decay, ZFP36 overexpression suppressed NOXA and JUN mRNA, and RNA immunoprecipitation showed ZFP36 associates with NOXA mRNA. BRAF inhibitor treatment increased wild-type ZFP36 levels, whereas ZFP36 mutants lacking phosphorylation sites had higher basal expression that did not increase with drug.
  • Sequential dabrafenib followed by AZD5991 produced 88% apoptosis at 60 h versus ≤30% with dabrafenib alone, while the reverse schedule was antagonistic; in vivo, sequential BRAF inhibitor followed by MCL-1 inhibitor S63845 or AZD5991 led to profound tumor regression, prolonged survival, and no pathologic evidence of residual tumors in three evaluated mice. Paired patient biopsies showed NOXA and DUSP4 mRNA suppressed after 10–15 days of vemurafenib.

Methods

  • In vitro: siRNA sensitization screen in 21 cancer cell lines using driver inhibitors (PLX4720, imatinib, gefitinib, lapatinib, crizotinib) across 40 nM to 10 µM with cell number measured after 48 h; dynamic BH3 profiling; western blot; qRT-PCR; actinomycin D assays; immunoprecipitation; RNA immunoprecipitation; Annexin-V apoptosis assays.
  • Clinical samples: paired melanoma biopsies from BRAF-mutant patients before and 10–15 days after vemurafenib, plus freshly obtained primary melanoma cells; samples collected under IRB-approved protocols.
  • Animal experiments: A375M xenografts in Nu/Nu mice treated with dabrafenib 30 mg/kg by oral gavage followed 7 h later by vehicle, AZD5991 100 mg/kg, or S63845 25 mg/kg intravenously daily up to 14 days; tumor volume, survival, and immunohistochemistry assessed. Statistical analyses included Holm–Sidak, ANOVA, t tests, and synergy scores.

Limitations

  • Stated: the authors cannot exclude other post-transcriptional mechanisms (e.g., other AU-rich binding proteins) or transcriptional regulation contributing to NOXA expression; because the ZFP36 family includes three AU-binding proteins, further work is needed to clarify the generality of ZFP36 essentiality in NOXA suppression.
  • Stated: optimal timing of MCL-1 inhibitors with MAPK inhibitors will require challenging schedule optimization due to drug pharmacokinetics/pharmacodynamics, and BIM levels should also be measured; BH3 profiling is hypothesized as a superior tool for dosing.
  • Stated: combined MAPK inhibitor/MCL-1 inhibitor therapy may not be effective where MAPK inhibitor resistance is associated with failure to suppress the MAPK pathway, and targeting adaptive resistance may be most useful before MAPK inhibitor resistance emerges.
  • Evident from the text: some primary patient dynamic BH3 profiling data are from n = 1 (Fig. 1f), and paired biopsy analysis is n = 1 with three technical replicates (Fig. 5a); in vivo efficacy is shown in A375M xenograft models rather than spontaneous tumors.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-019-12477-y

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Targeted therapies induce dependence on MCL-1. a Scheme for sensitization siRNA screen to targeted therapies. b Cell number following targeting of the anti-apoptotic BCL-2 family by siRNA and targeted therapies (10 µm), relative to vehicle-treated cells. PLX4720 was used for BRAF-mutant cells, imatinib was used for CKIT-mutant cells, gefitinib was used use for EGFR-mutant cells; crizotinib was used for MET- and ALK-mutant cells and lapatinib was used for ERBB2-amplified cells. Cell number was normalized to cells transfected with control siRNA and treated with drug vehicle. c, d, e Dynamic BH3 profiling (DBP) of cancer cell lines following 36 h treatment with the indicated drug (1 µm). Mitochondrial permeabilization is calculated relative to vehicle-treated cells. Statistical significance (n = 4) determined using the Holm–Sidak method. ***, adjusted P value < 0.001 comparing drug treatment vs vehicle control; **, adjusted P value < 0.01; *, adjusted P value < 0.05; §, adjusted P value < 0.1. Comparisons with adjusted P value ≥ 0.1 are designated without any symbol. f DBP profiles following BRAF (1 µm dabrafenib), MEK (0.1 µm trametinib), and ERK inhibitors (1 µM VX11e and SCH772984) on freshly obtained cells from melanoma patients (n = 1). See also Supplementary Fig. 1 and Supplementary Tables 1 and 2. Source data for siRNA screen are provided as a Source Data file. Error bars indicate mean ± s.e.m. of indicated replicates
Fig. 1 Targeted therapies induce dependence on MCL-1. a Scheme for sensitization siRNA screen to targeted therapies. b Cell number following targeting of the anti-apoptotic BCL-2 family by siRNA and targeted therapies (10 µm), relative to vehicle-treated cells. PLX4720 was used for BRAF-mutant cells, imatinib was used for CKIT-mutant cells, gefitinib was used use for EGFR-mutant cells; crizotinib was used for MET- and ALK-mutant cells and lapatinib was used for ERBB2-amplified cells. Cell number was normalized to cells transfected with control siRNA and treated with drug vehicle. c, d, e Dynamic BH3 profiling (DBP) of cancer cell lines following 36 h treatment with the indicated drug (1 µm). Mitochondrial permeabilization is calculated relative to vehicle-treated cells. Statistical significance (n = 4) determined using the Holm–Sidak method. ***, adjusted P value < 0.001 comparing drug treatment vs vehicle control; **, adjusted P value < 0.01; *, adjusted P value < 0.05; §, adjusted P value < 0.1. Comparisons with adjusted P value ≥ 0.1 are designated without any symbol. f DBP profiles following BRAF (1 µm dabrafenib), MEK (0.1 µm trametinib), and ERK inhibitors (1 µM VX11e and SCH772984) on freshly obtained cells from melanoma patients (n = 1). See also Supplementary Fig. 1 and Supplementary Tables 1 and 2. Source data for siRNA screen are provided as a Source Data file. Error bars indicate mean ± s.e.m. of indicated replicatesCC BY · PubMed Central
Fig. 2 Targeted therapies suppress NOXA mRNA. a Protein levels of BCL-2-family members following treatment of SK-MEL-5 melanoma cells treated PLX4720 (1 µm). b Effect of BRAF and MEK inhibitors on NOXA protein in A375M melanoma cells. c Effect of imatinib on NOXA in KIT-mutant GIST-T1 cells. d Changes in BCL-2 family mRNA expression following MEK inhibitor treatment as assessed in published microarray analysis (GSE20051). For each gene, the expression is normalized to that of DMSO-treated cells. e Effect of BRAF and MEK inhibitor on NOXA mRNA in A375M cells. Statistical significance of drug versus vehicle-treated cells (n = 3) was determined using Holm–Sidak multiple comparison test. ****, adjusted value < 0.0001. f Western blot of NOXA, BIM, and MCL1 in A375M cells expressing NOXA. g Effect of overexpression of NOXA on number of A375M cells following PLX4720 treatment (n = 3 per group). Statistical significance of growth inhibition was done using extra sum-of-squares F-test. **, adjusted P value < 0.01. h Effect of overexpression of NOXA on the growth of A375M xenografts on response to dabrafenib (n = 10 per group). Tumor size shown is relative to pre-treatment (day 22). Fold change in tumor volume at day 32 was compared using ANOVA with Sidak multiple comparison tests. *, adjusted P value < 0.05; **, adjusted P value < 0.01; ***, adjusted P value, < 0.001. Error bars indicate mean ± s.e.m. of indicated replicates. See also Supplementary Fig. 2. Source data for all Western blots are provided as a Source Data file
Fig. 2 Targeted therapies suppress NOXA mRNA. a Protein levels of BCL-2-family members following treatment of SK-MEL-5 melanoma cells treated PLX4720 (1 µm). b Effect of BRAF and MEK inhibitors on NOXA protein in A375M melanoma cells. c Effect of imatinib on NOXA in KIT-mutant GIST-T1 cells. d Changes in BCL-2 family mRNA expression following MEK inhibitor treatment as assessed in published microarray analysis (GSE20051). For each gene, the expression is normalized to that of DMSO-treated cells. e Effect of BRAF and MEK inhibitor on NOXA mRNA in A375M cells. Statistical significance of drug versus vehicle-treated cells (n = 3) was determined using Holm–Sidak multiple comparison test. ****, adjusted value < 0.0001. f Western blot of NOXA, BIM, and MCL1 in A375M cells expressing NOXA. g Effect of overexpression of NOXA on number of A375M cells following PLX4720 treatment (n = 3 per group). Statistical significance of growth inhibition was done using extra sum-of-squares F-test. **, adjusted P value < 0.01. h Effect of overexpression of NOXA on the growth of A375M xenografts on response to dabrafenib (n = 10 per group). Tumor size shown is relative to pre-treatment (day 22). Fold change in tumor volume at day 32 was compared using ANOVA with Sidak multiple comparison tests. *, adjusted P value < 0.05; **, adjusted P value < 0.01; ***, adjusted P value, < 0.001. Error bars indicate mean ± s.e.m. of indicated replicates. See also Supplementary Fig. 2. Source data for all Western blots are provided as a Source Data fileCC BY · PubMed Central
Fig. 3 ERK suppression decreases NOXA expression via TTP/ZFP36. a Quantification of NOXA mRNA following treatment of BRAF-mutant A375M cells with MEK or BRAF inhibitors. b NOXA mRNA upon treatment with actinomycin D with or without BRAF inhibitor treatment (n = 2–3 per group). c Consensus sequence of binding sites for TTP/ZFP36 family proteins depicting the location of putative AU-rich sequences in NOXA mRNA. d Quantification of indicated mRNAs following transfection of A375M cells with siRNAs targeting ZFP36 family (n = 3). Statistical comparison was done using one-way ANOVA with Dunnett’s multiple comparison test. *, adjusted P value < 0.05; **, adjusted P value < 0.01; ***, adjusted P value < 0.001. e Quantification of knockdown of ZFP36 using independent siRNAs. Statistical significance was determined by ANOVA with Dunnett’s multiple comparison test (n = 3). *, adjusted P value < 0.05; **, adjusted P value < 0.01. n = 3. f Effect of suppression of ZFP36/TTP on NOXA mRNA following Actinomycin D treatment (n = 3). Statistical significance was determined using extra sum-of-squares F-test. ***, adjusted P value < 0.001. g Effect of ZFP36 expression on JUN, NOXA, and E2F4 mRNAs in A375M cells (n = 3 per group). Statistical comparison of ZFP36 expressing cells compared to control cells was done using t test. ***, adjusted P value < 0.001; **, adjusted P value < 0.01. h Quantification of NOXA mRNA associated with immunoprecipitated ZFP36. Statistical comparison of ZFP36 expressing cells compared to control cells was done using t test. (n = 3). **, adjusted P value < 0.01; ****, adjusted P value < 0.0001. i The sequence of ZFP36 with putative MAPK phosphorylation sites. j Effect of dabrafenib on wild-type and mutant ZFP36 in A375M cells. Error bars indicate mean ± s.e.m. of indicated replicates. See also Supplementary Fig. 3. Source data for all Western blots are provided as a Source Data file
Fig. 3 ERK suppression decreases NOXA expression via TTP/ZFP36. a Quantification of NOXA mRNA following treatment of BRAF-mutant A375M cells with MEK or BRAF inhibitors. b NOXA mRNA upon treatment with actinomycin D with or without BRAF inhibitor treatment (n = 2–3 per group). c Consensus sequence of binding sites for TTP/ZFP36 family proteins depicting the location of putative AU-rich sequences in NOXA mRNA. d Quantification of indicated mRNAs following transfection of A375M cells with siRNAs targeting ZFP36 family (n = 3). Statistical comparison was done using one-way ANOVA with Dunnett’s multiple comparison test. *, adjusted P value < 0.05; **, adjusted P value < 0.01; ***, adjusted P value < 0.001. e Quantification of knockdown of ZFP36 using independent siRNAs. Statistical significance was determined by ANOVA with Dunnett’s multiple comparison test (n = 3). *, adjusted P value < 0.05; **, adjusted P value < 0.01. n = 3. f Effect of suppression of ZFP36/TTP on NOXA mRNA following Actinomycin D treatment (n = 3). Statistical significance was determined using extra sum-of-squares F-test. ***, adjusted P value < 0.001. g Effect of ZFP36 expression on JUN, NOXA, and E2F4 mRNAs in A375M cells (n = 3 per group). Statistical comparison of ZFP36 expressing cells compared to control cells was done using t test. ***, adjusted P value < 0.001; **, adjusted P value < 0.01. h Quantification of NOXA mRNA associated with immunoprecipitated ZFP36. Statistical comparison of ZFP36 expressing cells compared to control cells was done using t test. (n = 3). **, adjusted P value < 0.01; ****, adjusted P value < 0.0001. i The sequence of ZFP36 with putative MAPK phosphorylation sites. j Effect of dabrafenib on wild-type and mutant ZFP36 in A375M cells. Error bars indicate mean ± s.e.m. of indicated replicates. See also Supplementary Fig. 3. Source data for all Western blots are provided as a Source Data fileCC BY · PubMed Central
Fig. 4 Targeted therapies reconfigure apoptotic signaling and create a schedule-dependent vulnerability. a Effect of PLX4720 (1 µm) on total levels of NOXA and BCL-2 family members in A375M melanoma cells (input for immunoprecipitation). b Association of MCL-1 with NOXA and BIM following PLX4720 treatment. c Association of BIM with MCL-1 following PLX4720 treatment. d Effect of A1210477, dabrafenib or both on MCL-1 and BIM. e Effect of A1210477, dabrafenib or both on the association of protein levels of MCL-1, BIM, and NOXA. f Scheduling of drug treatments in g. g Representative synergy blot of A-121044 followed by dabrafenib, or reverse, in A375M cells. h Effect of dabrafenib followed by AZD5991 on apoptosis in A375M cells. Cells were treated with vehicle (time 0) or dabrafenib (1 µm) for the indicated time, followed by 16 h exposure to AZD5991 (1 µm) or equal volume vehicle. Statistical comparison (n = 4) of different drug schedules was done using two-way ANOVA with Sidak’s multiple comparison test. *, adjusted P value < 0.05; ****, adjusted P value, < 0.0001. i Effect of dabrafenib followed by A1210477 on apoptosis in IPC-298 cells (n = 4). Cells were treated as in h. j Synergy scores of A375M, GIST-T1 or PC9 cells treated with MCL-1 or BCL-2 inhibitors with targeted agents. Statistical comparison was done using one-way ANOVA with Holm–Sidak’s multiple comparison test. ****, adjusted P value < 0.0001; ***, adjusted P value < 0.001; **, adjusted P value < 0.01. Error bars indicate mean ± s.e.m. of indicated replicates. See also Supplementary Fig. 4. Source data for all western blots are provided as a Source Data file
Fig. 4 Targeted therapies reconfigure apoptotic signaling and create a schedule-dependent vulnerability. a Effect of PLX4720 (1 µm) on total levels of NOXA and BCL-2 family members in A375M melanoma cells (input for immunoprecipitation). b Association of MCL-1 with NOXA and BIM following PLX4720 treatment. c Association of BIM with MCL-1 following PLX4720 treatment. d Effect of A1210477, dabrafenib or both on MCL-1 and BIM. e Effect of A1210477, dabrafenib or both on the association of protein levels of MCL-1, BIM, and NOXA. f Scheduling of drug treatments in g. g Representative synergy blot of A-121044 followed by dabrafenib, or reverse, in A375M cells. h Effect of dabrafenib followed by AZD5991 on apoptosis in A375M cells. Cells were treated with vehicle (time 0) or dabrafenib (1 µm) for the indicated time, followed by 16 h exposure to AZD5991 (1 µm) or equal volume vehicle. Statistical comparison (n = 4) of different drug schedules was done using two-way ANOVA with Sidak’s multiple comparison test. *, adjusted P value < 0.05; ****, adjusted P value, < 0.0001. i Effect of dabrafenib followed by A1210477 on apoptosis in IPC-298 cells (n = 4). Cells were treated as in h. j Synergy scores of A375M, GIST-T1 or PC9 cells treated with MCL-1 or BCL-2 inhibitors with targeted agents. Statistical comparison was done using one-way ANOVA with Holm–Sidak’s multiple comparison test. ****, adjusted P value < 0.0001; ***, adjusted P value < 0.001; **, adjusted P value < 0.01. Error bars indicate mean ± s.e.m. of indicated replicates. See also Supplementary Fig. 4. Source data for all western blots are provided as a Source Data fileCC BY · PubMed Central
Fig. 5 Targeting apoptotic adaptation overcomes resistance to targeted therapy in vivo. a Comparison of NOXA and DUSP4 mRNA in paired biopsies obtained from melanoma patients before treatment with vemurafenib (pre-treatment) and 10–15 days later. Statistical comparison was done using ANOVA with Sidak’s multiple comparison test. ****, adjusted P value < 0.0001; **, adjusted P value < 0.001; *, adjusted P value < 0.05. n = 1 with three technical replicates. b BH3 profiling of A375M melanoma xenografts (n = 2) following treatment with dabrafenib in vivo. BIM peptide measures BCL-2 family member dependence, whereas MS1 and NOXA peptides measure dependence on MCL-1. Statistical comparison was done using one-way ANOVA with Dunnett’s multiple comparison test. *, adjusted P value < 0.05. c Timing of drug treatment of murine melanoma models. Arrows indicate time of drug treatment per day. d Weight of mice treated with BRAF inhibitor, MCL1 inhibitor S63845 or sequential administration of BRAF inhibitor followed by MCL1 inhibitors (n = 8 per group). e Change in A375M xenograft tumor volume following treatment with MCL1, BRAF, or sequential BRAF/MCL1 inhibitors. Statistical comparison of change of dabrafenib versus dabrafenib → S63845-treated animals was done using two-away ANOVA with Sidak multiple comparison tests (n = 14–16). **, adjusted P value < 0.005. f Change in A375M xenograft tumor volume after 14 days treatment (relative to pre-treatment tumor volume) following treatment with structurally distinct MCL1 inhibitors, BRAF inhibitor, or sequential administration of BRAF inhibitor followed by MCL1 inhibitors. Statistical comparison with vehicle-treated animal was done one-way ANOVA with multiple comparison tests. ***, adjusted P value < 0.001. g Overall survival of A375M xenograft models following treatment with MCL1, BRAF or sequential BRAF/MCL1 inhibitors. Statistical comparison was performed using Log-rank (Mantel–Cox) test. *, P value < 0.05. h Evaluation of residual tumors in mice treated with dabrafenib followed by S63845. Scale bar = 100 µm. For d, e, f, n = 14–16 per group. Error bars indicate mean ± s.e.m. of indicated replicates. See also Supplementary Fig. 5. Source data for all Western blots are provided as a Source Data file
Fig. 5 Targeting apoptotic adaptation overcomes resistance to targeted therapy in vivo. a Comparison of NOXA and DUSP4 mRNA in paired biopsies obtained from melanoma patients before treatment with vemurafenib (pre-treatment) and 10–15 days later. Statistical comparison was done using ANOVA with Sidak’s multiple comparison test. ****, adjusted P value < 0.0001; **, adjusted P value < 0.001; *, adjusted P value < 0.05. n = 1 with three technical replicates. b BH3 profiling of A375M melanoma xenografts (n = 2) following treatment with dabrafenib in vivo. BIM peptide measures BCL-2 family member dependence, whereas MS1 and NOXA peptides measure dependence on MCL-1. Statistical comparison was done using one-way ANOVA with Dunnett’s multiple comparison test. *, adjusted P value < 0.05. c Timing of drug treatment of murine melanoma models. Arrows indicate time of drug treatment per day. d Weight of mice treated with BRAF inhibitor, MCL1 inhibitor S63845 or sequential administration of BRAF inhibitor followed by MCL1 inhibitors (n = 8 per group). e Change in A375M xenograft tumor volume following treatment with MCL1, BRAF, or sequential BRAF/MCL1 inhibitors. Statistical comparison of change of dabrafenib versus dabrafenib → S63845-treated animals was done using two-away ANOVA with Sidak multiple comparison tests (n = 14–16). **, adjusted P value < 0.005. f Change in A375M xenograft tumor volume after 14 days treatment (relative to pre-treatment tumor volume) following treatment with structurally distinct MCL1 inhibitors, BRAF inhibitor, or sequential administration of BRAF inhibitor followed by MCL1 inhibitors. Statistical comparison with vehicle-treated animal was done one-way ANOVA with multiple comparison tests. ***, adjusted P value < 0.001. g Overall survival of A375M xenograft models following treatment with MCL1, BRAF or sequential BRAF/MCL1 inhibitors. Statistical comparison was performed using Log-rank (Mantel–Cox) test. *, P value < 0.05. h Evaluation of residual tumors in mice treated with dabrafenib followed by S63845. Scale bar = 100 µm. For d, e, f, n = 14–16 per group. Error bars indicate mean ± s.e.m. of indicated replicates. See also Supplementary Fig. 5. Source data for all Western blots are provided as a Source Data fileCC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 38 Not checked · 108 Own results and interpretations

72 more claims

Create a free account to see all 146 claims and to verify the 65 references still open.

See all claims — free account
  • It may state two separate claims as one. 42
  • Probably not a substantial claim. 31
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 71 references

Cited by

See all 80

Metadata

Authors
Montero, J., Gstalder, C., Kim, D. J., Sadowicz, D., Miles, W., Manos, M., Cidado, J. R., Paul Secrist, J., Tron, A. E., Flaherty, K., Stephen Hodi, F., Yoon, C. H., Letai, A., Fisher, D. E., & Haq, R.
Affiliations
  • Harvard University (US)
  • The Ohio State University (US)
  • AstraZeneca (United States) (US)
  • Brigham and Women's Hospital (US)
Corresponding author
  • Fisher, David E.
  • Haq, Rizwan
Venue
Nature Communications
Published
2019-11-14
Volume
10
Issue
1
Pages
5157-5157
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2984379013
Cited by
80
References
71
Citations by year
2026: 7 · 2025: 5 · 2024: 8 · 2023: 16 · 2022: 10 · 2021: 15 · 2020: 16
FWCI
2.68
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Melanoma Research Alliance
  • O’Connor-MacGregor Fund for Melanoma Research
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords
Noxa, mRNA destabilization, Mcl-1, Bcl-2 family proteins, drug resistance, targeted cancer therapy, BRAF inhibitors, EGFR inhibitors, apoptosis, adaptive resistance, melanoma, Mcl-1 inhibitors
MeSH terms
Animals, Base Sequence, Humans, Male, Mice, Nude, RNA, Messenger, Signal Transduction, Apoptosis, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-bcl-2, RNA Stability, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Tristetraprolin, Molecular Targeted Therapy, Myeloid Cell Leukemia Sequence 1 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. https://app.cochat.ai/papers/10.1038/s41467-019-12477-y
The paper
Montero, J., Gstalder, C., Kim, D. J., Sadowicz, D., Miles, W., Manos, M., Cidado, J. R., Paul Secrist, J., Tron, A. E., Flaherty, K., Stephen Hodi, F., Yoon, C. H., Letai, A., Fisher, D. E., & Haq, R. (2019). Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. Nature Communications. https://doi.org/10.1038/s41467-019-12477-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.